• Consequently, EPB-348 Phase 2b/3 trials can go against placebo for both antiviral (cutaneous) and pain endpoints Previous clinical studies with Acyclovir, Valtrex and Famvir suggest that they may have some impact on reducing pain & PHN • The pain impact of these antivirals have not been proven in suf